REG - Avacta Group PLC - Pre|CISION® payload release vs approved ADCs

AvactaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260506:nRSF1310Da&default-theme=true

RNS Number : 1310D  Avacta Group PLC  06 May 2026

 

 

Avacta presents new comparisons of pre|CISION(®) payload release vs approved
ADCs and AVA6207 dual payload delivery at Science Day 2026

 

 

LONDON and PHILADELPHIA - May 6, 2026 - Avacta Therapeutics (AIM: AVCT, "the
Company", "Avacta"), a clinical stage biopharmaceutical company developing
pre|CISION(®), a tumor-activated oncology delivery platform, will today
present two new developments at its Science Day 2026 event.

 

The Company is presenting comparative analyses of pre|CISION(®) payload
delivery via one of its programs, AVA6103, compared with now two approved
Antibody-Drug Conjugates (ADCs).It is also presenting updated in vivo studies
of the dual payload delivery system in another program, AVA6207.

 

Christina Coughlin, CEO of Avacta, commented:

 

"These presentations further underline the potential of our unique
pre|CISION(®) technology to improve treatment options for cancer patients.

 

"Providing data analysis of two ADCs, including Enhertu(®), as part of the
AVA6103 program, further demonstrates the alignment of the ADC mechanism and
highlights the critical advantages of our pre|CISION(®) delivery directly to
the tumor with higher selectivity, regardless of the ADC target.

 

"The data with our pre|CISION technology to deliver dual payloads has now
demonstrated for the first time an efficacy advantage over single payload ADCs
in a FAP-low and HER2-positive patient-derived cancer model.

 

"We continue to build momentum and enhance our IP - at a pace that we are
confident exceeds industry norms."

 

 

AVA6103: The new data analyses in the AVA6103 program comparing pre|CISION(®)
FAP-cleavable exatecan delivery with those of leading marketed ADCs have been
extended to Datroway(®), an ADC targeting the TROP2 antigen, as well as
Enhertu(®) an ADC targeting the HER2 antigen.

 

Details of these studies:

·    All three of these drugs (AVA6103, Enhertu(®) and Datroway(®))
feature tumor-targeted delivery of topoisomase I inhibitors (exatecan or
deruxtecan) and these comparisons are designed to address the differences in
the payload delivery and control for the differences in cancer models

·    The delivery kinetics of exatecan (derived from AVA6103) and
deruxtecan (derived from Enhertu(®) or Datroway(®)) demonstrate more rapid
tumor penetration of released exatecan from AVA6103 (T(max) of minutes,
AVA6103 versus T(max) >24 hours, Enhertu(®) or Datroway(®)) and higher
maximal concentration (C(max)) of released payload in the tumor with
differences observed of over 1-log

·    The tumor selectivity index (TSI) is a measure of the overall
exposure (area under the curve, AUC) in the tumor vs. the bloodstream (TSI =
AUC tumor/plasma ) which is at least 3 times higher with released exatecan
from AVA6103 than either released deruxtecan from Enhertu(®) or Datroway(®)

·    The Company is planning to publish these findings at an upcoming
academic meeting and in a peer-reviewed journal

 

AVA6207: The in vivo data in the AVA6207 program show the dual payload
delivery demonstrating prolonged deep complete responses despite tumor
regrowth with the conventional cytotoxic drugs. Initial data was published at
AACR 2026 last month and has been updated.

 

Findings include:

·    Results indicate that deep and durable complete responses are
observed in the FAP-high model, HEK-FAP where tumors regrow with conventional
therapy.

·    In the FAP-low/HER2-positive patient derived xenograft model of
gastric cancer, durable responses with AVA6207 are observed where tumor
regrowth is observed with Enhertu(®). These results suggest optimal treatment
with the combination is more effective in this model than the deruxtecan-based
ADC.

 

The investor Science Day 2026 event is being held at the Royal Society of
Chemistry, Burlington House, Piccadilly, London W1J 0BA, starting at
10.30am. Attendance capacity is limited, so attendance is limited to those who
have received confirmation of registration previously. The presentations will
be recorded and published on the Company website in due course.

 

Enhertu(®) is a registered trademark of Daiichi Sankyo Company, Limited and
AstraZeneca. Datroway(®) is a registered trademark of Daiichi Sankyo Company,
Limited.

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION®
platform. pre|CISION® is a payload delivery system based on a tumor-specific
protease (Fibroblast Activation Protein or FAP) that is designed to
concentrate highly potent payloads in the tumor microenvironment while sparing
normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC)
are a novel entry to the XDC drug class, leveraging the success of antibody
drug conjugates with alternative methods of delivery beyond antibodies.

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to
provide unique benefits over traditional antibody drug conjugates, releasing
active payload in the tumor and reducing systemic exposure and toxicity which
enables dosing to be optimized to deliver the best outcomes for patients. The
lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled
pre|CISION® version of doxorubicin that delivers the payload directly in the
tumor with limited peripheral blood exposure and has demonstrated preliminary
activity in tumor types sensitive to doxorubicin including salivary gland
cancer and soft tissue sarcoma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESUVVWRNKUVRAR



            Copyright 2019 Regulatory News Service, all rights reserved